{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:59:41Z","timestamp":1769014781554,"version":"3.49.0"},"reference-count":27,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,11,14]]},"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the prevalence and quality of antipsychotic prescribing for people with intellectual disability (ID).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A clinical audit of prescribing practice in the context of a quality improvement programme. Practice standards for audit were derived from relevant, evidence-based guidelines, including NICE. Data were mainly collected from the clinical records, but to determine the clinical rationale for using antipsychotic medication in individual cases, prescribers could also be directly questioned.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Settings<\/jats:title>\n                    <jats:p>54 mental health services in the UK, which were predominantly NHS Trusts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Information on prescribing was collected for 5654 people with ID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Almost two-thirds (64%) of the total sample was prescribed antipsychotic medication, of whom almost half (49%) had a schizophrenia spectrum or affective disorder diagnosis, while a further third (36%) exhibited behaviours recognised by NICE as potentially legitimate targets for such treatment such as violence, aggression or self-injury. With respect to screening for potential side effects within the past year, 41% had a documented measure of body weight (range across participating services 18\u2013100%), 32% blood pressure (0\u2013100%) and 37% blood glucose and blood lipids (0\u2013100%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data from mental health services across the UK suggest that antipsychotic medications are not widely used outside of licensed and\/or evidence-based indications in people with ID. However, screening for side effects in those patients on continuing antipsychotic medication was inconsistent across the participating services and the possibility that a small number of these services failed to meet basic standards of care cannot be excluded.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-013116","type":"journal-article","created":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T21:10:34Z","timestamp":1480972234000},"page":"e013116","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["Quality of prescribing of antipsychotic medication for people with intellectual disability under the care of UK mental health services: a cross-sectional audit of clinical practice"],"prefix":"10.1136","volume":"6","author":[{"given":"Carol","family":"Paton","sequence":"first","affiliation":[{"name":"Oxleas NHS Foundation Trust, Dartford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumera","family":"Bhatti","sequence":"additional","affiliation":[{"name":"Royal College of Psychiatrists Centre for Quality Improvement, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Purandare","sequence":"additional","affiliation":[{"name":"Central and North East London Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Roy","sequence":"additional","affiliation":[{"name":"Coventry and Warwickshire Partnership Trust, Coventry, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TRE","family":"Barnes","sequence":"additional","affiliation":[{"name":"Imperial College, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,12,5]]},"reference":[{"key":"2025120518590045000_6.12.e013116.1","unstructured":"National Institute for Health and Care Excellence. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. NICE Guideline 11 (NG11). 2015. https:\/\/www.nice.org.uk\/guidance\/ng11"},{"key":"2025120518590045000_6.12.e013116.2","first-page":"385","article-title":"Psychotropic drugs and mental retardation: disabilities and the prescription of drugs for behaviour and for epilepsy in three residential settings","volume":"34","author":"Clarke","year":"1990","journal-title":"J Ment Deficiency Res"},{"key":"2025120518590045000_6.12.e013116.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.1995.tb00518.x"},{"key":"2025120518590045000_6.12.e013116.4","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.106.022483"},{"key":"2025120518590045000_6.12.e013116.5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2788.1999.043005360.x"},{"key":"2025120518590045000_6.12.e013116.6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21500","article-title":"Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomised controlled trial (NACHBID)","volume":"21","author":"Tyrer","year":"2009","journal-title":"Health Technol Assess"},{"key":"2025120518590045000_6.12.e013116.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2008.08.007"},{"key":"2025120518590045000_6.12.e013116.8","unstructured":"Department of Health. Transforming care: a national response to Winterbourne View hospital. Department of Health, 2012."},{"key":"2025120518590045000_6.12.e013116.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.2011.01421.x"},{"key":"2025120518590045000_6.12.e013116.10","unstructured":"Deb S , Clarke D , Unwin G . Using Medication to Manage Behaviour Problems among Adults with a Learning Disability. University of Birmingham, 2006. http:\/\/www.ld-medication.bham.ac.uk\/"},{"key":"2025120518590045000_6.12.e013116.11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/j.2051-5545.2009.tb00248.x","article-title":"International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities","volume":"8","author":"Deb","year":"2009","journal-title":"World Psychiatry"},{"key":"2025120518590045000_6.12.e013116.12","unstructured":"National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: treatment and management. NICE Guideline (CG178), 2014. https:\/\/www.nice.org.uk\/guidance\/cg178"},{"key":"2025120518590045000_6.12.e013116.13","unstructured":"ICD-10. World Health Organisation. 2015. http:\/\/apps.who.int\/classifications\/icd10\/browse\/2015\/en#\/V"},{"key":"2025120518590045000_6.12.e013116.14","unstructured":"Formic software. http:\/\/www.formic.com\/survey-software\/"},{"key":"2025120518590045000_6.12.e013116.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4326"},{"key":"2025120518590045000_6.12.e013116.16","unstructured":"Glover G , Williams R . Prescribing of psychotropic drugs to people with learning disabilities and\/or autism by general practitioners in England. Public Health England, 2015. PHE publications gateway number:2015105. http:\/\/www.improvinghealthandlives.org.uk\/securefiles\/160131_1129\/\/Psychotropic%20medication%20and%20people%20with%20learning%20disabilities%20or%20autism.pdf"},{"key":"2025120518590045000_6.12.e013116.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rasd.2014.03.021"},{"key":"2025120518590045000_6.12.e013116.18","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225020-00004"},{"key":"2025120518590045000_6.12.e013116.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.09.023"},{"key":"2025120518590045000_6.12.e013116.20","unstructured":"Banerjee S . The use of antipsychotic medication for people with dementia: time for action. Department of Health, 2009. http:\/\/www.rcpsych.ac.uk\/pdf\/Antipsychotic%20Bannerjee%20Report.pdf"},{"key":"2025120518590045000_6.12.e013116.21","unstructured":"National Institute for Health and Care Excellence. Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. NICE Guideline (CG185), 2014. https:\/\/www.nice.org.uk\/guidance\/cg185"},{"key":"2025120518590045000_6.12.e013116.22","unstructured":"National Institute for Health and Care Excellence. Depression in adults. NICE Guideline (CG90). 2009. https:\/\/www.nice.org.uk\/guidance\/cg178"},{"key":"2025120518590045000_6.12.e013116.23","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-012-1617-6"},{"key":"2025120518590045000_6.12.e013116.24","unstructured":"National Institute for Health and Care Excellence. Violence and aggression: short-term management in mental health, health and community settings. NICE Guideline (NG10), 2015. http:\/\/www.nice.org.uk\/guidance\/ng10"},{"key":"2025120518590045000_6.12.e013116.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-007633"},{"key":"2025120518590045000_6.12.e013116.26","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.113.142521"},{"key":"2025120518590045000_6.12.e013116.27","doi-asserted-by":"crossref","unstructured":"Williams K , Brignell A , Randall M , et al . Selective serotonin re-uptake inhibitors for treating people with autism spectrum disorders. Cochrane Database Syst Rev 2013;(8):CD004677. http:\/\/www.cochrane.org\/CD004677\/BEHAV_selective-serotonin-reuptake-inhibitors-for-treating-people-with-autism-spectrum-disorders","DOI":"10.1002\/14651858.CD004677.pub3"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-013116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T02:59:11Z","timestamp":1764989951000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-013116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12,5]]},"published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1136\/bmjopen-2016-013116"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-013116","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}